

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A.

for the period from January 1, 2013, to December 31, 2013.

comprising:

INTRODUCTION TO THE FINANCIAL STATEMENTS

BALANCE SHEET

PROFIT AND LOSS ACCOUNT

FUNDS FLOW STATEMENT

CASH FLOW STATEMENT

NOTES TO THE FINANCIAL STATEMENTS

The financial statement were presented by the Management Board composed of:

Adam Rozwadowski President of the Management Board signature:

Jacek Rozwadowski Deputy President of the Management Board signature:

The financial statements were drawn up by: Żaneta Bujalska signature:

Place: Warsaw, dated March 19, 2014.

**STATEMENT OF THE MANAGEMENT BOARD CONCERNING THE FINANCIAL STATEMENT OF
CENTRUM MEDYCZNE ENEL-MED S.A.**

for the period
from January 1, 2013, to December 31, 2013.

Pursuant to the Accounting Act dated September 29, 1994, the Management Board of the Company provided for drawing up the annual financial statements which present fairly and clearly all information relevant to the appraisal of the material and financial position of the Company as at December 31, 2013 and of its financial result for the financial year from January 1, 2013, to December 31, 2013. While drawing up the financial statements, the Management Board of the Company ensured the choice of relevant principles of valuation and preparation of the financial statements.

The financial statements comprise:

introduction to the financial statements,

balance sheet as at December 31, 2013, showing the balance sheet assets and liabilities in the amount of PLN 107,552 thousand;

profit and loss account for the period from January 1, 2013, to December 31, 2013, showing the net profit in the amount of PLN 467 thousand;

funds flow statement for the period from January 1, 2013, to December 31, 2013, showing the increase in equity by the amount of PLN 467 thousand;

cash flow statement for the period from January 1, 2013, to December 31, 2013, showing the decrease in net cash by the amount of PLN 29 thousand;

notes to the financial statements.

For the valuation of assets and liabilities and the measurement of the financial result, it was assumed that the company would continue its operations as a going concern in the foreseeable future on a scale that is not significantly reduced, which is in accordance with actual and legal status. The Management Board of the Company is responsible for the performance of accounting duties provided for in the provisions of law.

Adam Rozwadowski President of the Management Board signature:

Jacek Rozwadowski Deputy President of the Management Board signature:

The financial statements were drawn up by: Żaneta Bujalska signature:

Place: Warsaw, dated March 19, 2014.

INTRODUCTION TO THE FINANCIAL STATEMENTS

1. Information about the Company

Centrum Medyczne Enel-Med was established pursuant to the notarial deed drawn up on December 22, 2006, Reg. No. 5930/2006 under the business name of Centrum Medyczne Enel-Med Spółka Akcyjna. The last amendment to the articles of association was made on February 11, 2010, pursuant to the notarial deed Reg. No. 360/2010.

On February 28, 2007, the Company was entered into the National Court Register under number KRS 0000275255.

The registered office of the Company is located in Warsaw, ul. Słomińskiego 19, unit 524. The Company was assigned the following REGON identification number: 140802685

The core business of the Company includes:

- General medical practice activities (PKD 8621Z)
- Specialist medical practice activities (PKD 8622Z)
- Physiotherapy activities (PKD 8690A)
- Dental practice activities (PKD 8623Z)
- Other human health care activities, n.e.c. (PKD 8690Z).

2. Duration of the Company

The Company was established for an indefinite period of time.

3. Periods for which historical financial information is presented

The period covered by the financial statements presented:

- from January 1, to December 31, 2013.

The periods for which comparable financial data is presented:

- from January 1, to December 31, 2012.

4. Composition of management and supervisory bodies of the Company:

Management Board of the Company:

- Adam Stanisław Rozwadowski - President of the Management Board
- Jacek Jakub Rozwadowski - Deputy President of the Management Board

Supervisory Board of the Company

- Anna Maria Rozwadowska
- Janusz Ryszard Jakubowski
- Anna Piszcz
- Zbigniew Okoński
- Adam Ciuhak

5. Information whether the financial statements and comparable data include consolidated data

The financial statements and comparable financial data do not include consolidated data. The Company does not have any undertakings which draw up independent financial statements.

6. Information whether the Company is a parent undertaking, a partner in a co-subsiary, or a significant investor, and whether it draws up consolidated financial statements

The Company is a parent undertaking for the following companies: Enelbud Sp. z o.o., Centrum Medyczne Diagnostyka Sp. z o.o. and Centrum Medyczne Diagnostyka Obrazowa Sp. z o.o. The Company does not draw up consolidated financial statements under the exemption arising from Article 58 of the Accounting Act. The Company is indirectly connected with Bonus Vitae Sp. z o.o. for which it is a significant investor through Enelbud sp. z o.o., its subsidiary. The Company is not a partner of co-subsidiary undertaking or a significant investor in other entities.

7. Information on merger of companies during the period covered by these financial statements and comparable data

Not applicable.

8. Going on concern assumption

The financial statements were drawn up with the assumption that the Company will continue its operations as a going concern in the foreseeable future and that it will not and does not have to discontinue the operations or significantly reduce their scope.

9. Comparability of data

The financial statements and comparable data are presented in a manner ensuring their comparability through applying consistent accounting principles in all presented periods, in accordance with the accounting principles applied by the Company to the preparation of the financial statements for the last period, and through the recognition of adjustments for errors in the periods to which they refer, regardless of the period in which they were entered into the account books.

The presented financial statements and comparable financial data do not include any adjustments made which arise from the qualifications included in the opinions of the entities entitled to audit financial statements for the years for which the financial statements or comparable financial data are presented.

10. Description of adopted accounting principles (policy), including methods of valuation of assets and liabilities (including amortisation and depreciation), measurement of revenues, costs and financial result, and the manner of drawing up the financial statements and comparable data

The accounting principles adopted for the preparation of the financial statements comply with the Accounting Act dated September 29, 1994, as amended, hereinafter referred to as the Act.

Assets and liabilities are valued based on expenditures actually incurred for their acquisition, subject to the prudence principle.

a) Tangible fixed assets and intangible assets

Tangible assets include fixed assets and equivalent assets of anticipated economic useful life longer than one year, suitable for use, and intended for use for the purposes of the undertaking.

Intangible assets include property rights used by the undertaking to carry out business activity whose anticipated economic useful life is longer than one year.

Intangible assets are valued according to their acquisition prices, costs of manufacture or re-assessed value minus accumulated amortisation or depreciation as well as impairment write-downs.

Tangible fixed assets include also external fixed assets used by the entity pursuant to lease agreements if the agreement fulfils the terms and conditions specified in the Act.

Fixed assets under construction include future tangible fixed assets in the period of their construction, assembly or improvement of the existing tangible assets which are classified as tangible fixed assets.

Advances for fixed assets include cash or cash equivalents transferred to the suppliers on account of future supplies of tangible assets and fixed assets under construction.

Tangible fixed assets are stated in the financial statements at their net book value, that is pursuant to their initial value minus accumulated depreciation and impairment write-downs. The initial value of tangible assets and fixed assets under construction comprise the total costs incurred by the undertaking for the period of construction, assembly and improvement or adaptation of an asset of use, including also the goods and services tax which is not deductible, and the costs of assumed liabilities minus the income arising therefrom. In particular, the costs of liabilities subject to capitalisation may include interest, commissions and foreign exchange gains and losses on credits and loans, as well as advance payments and trade liabilities for the period of construction. The revenues decreasing the capitalised costs may refer to the interest received on investment of temporarily unused cash from incurred liabilities

Impairment write-downs are made when it is highly probable that a tangible fixed asset controlled by the undertaking will not generate in the future a significant portion or all of anticipated economic benefits. Should there be any changes as regards production technology, intending for liquidation, decommissioning or other reasons causing the impairment of a tangible asset, appropriate revaluation write-off is made and charged to other operating costs.

Amortisation/depreciation is made according to the straight-line method. Accumulated amortisation charges are made beginning from the month following the month of commissioning a tangible asset or intangible asset.

The accuracy of assumed useful lives and other data is periodically verified by the manager of the undertaking, which results in relevant adjustment of annual rates and amounts of accumulated amortisation charges beginning from the first month of the next financial year.

The Company applies the following annual rates for the basic categories of tangible assets:

buildings, premises and civil engineering structures: 3.8%

plant and machinery: 10-30%

means of transportation: 12.5-40%

other fixed assets: 10%-20%

The Company applies the following annual rates for the basic categories of intangible assets:

copyright or related and neighbouring rights: 50%

licences: 50%

other: 20-50%

Fixed assets under construction and land, including the perpetual usufruct of land, are not depreciated.

(b) Investments

Investments include the assets acquired in order to derive economic benefits resulting from their incremental value, to generate revenues in the form of interest, dividends, or other benefits, including the benefits from commercial transactions, in particular financial assets as well as

immovable property and intangible assets that are not used by the undertaking but have been acquired solely in order to derive benefits.

Immovable property and intangible assets classified as investments are valued according to the principles specified for tangible assets/intangible assets. Long-term investments other than immovable property and intangible assets classified as investments are valued according to the acquisition price net of impairment write-downs.

Long-term shares in subordinated undertakings are valued according to the acquisition price net of impairment write-downs.

The increase in value of investments classified as fixed assets increases the revaluation reserve (fund).

A decrease in the value of previously reassessed investment to the amount added to the revaluation reserve decreases the investment value and the revaluation reserve. In other cases, the decrease in the investment value is classified as financial costs. An increase in value of a given investment directly relating to a previous decrease thereof charged to cost of financial activities, is recognised as income from financial activities up to the amount of such cost.

Short-term investments are valued according to their acquisition price.

Granted loans are stated according to the adjusted acquisition price.

(c) Receivables

Receivables are classified as long-term receivables if their maturity is more than one year as at the balance sheet date, and are classified as short-term receivables if their maturity is less than one year as at the balance sheet date.

As at the balance sheet date, receivables are valued at the amounts due, together with the calculated default interest on payment of amounts due and are stated at the net value (i.e. net of revaluation write-offs).

Receivables are revalued depending on the degree of probability of their receipt by making revaluation write-offs charged to other operating costs or costs of financial activities, depending on the type of receivable.

Receivables relative to taxes, subsidies and social insurance as well as other receivables are valued at the amounts due according to the regulations, agreements or other documents.

(d) Inventories

Inventories are valued pursuant to their actual purchase prices or the actual costs of their manufacture which are not higher than the net selling prices.

The acquisition price is the actual purchase price of materials consisting of the amount due to the seller (without input tax on goods and services and excise duty), and in the case of imports - plus the public and legal charges, and plus the costs directly related to the purchase, together with the costs of transport, loading and unloading, and net of price reductions (discounts, rebates).

Revaluation write-offs for inventories made in connection with their impairment and arising from the valuation pursuant to net selling prices instead of purchase prices or costs of manufacture are

classified respectively to other operating costs (materials), costs of manufacture of sold products (finished goods), or costs of sale (goods).

The outflow of stock is determined pursuant to the FIFO method.

(e) Monetary assets

Monetary assets include cash in hand, cash at bank, cash deposits payable within 3 months, and cheques, external bills of exchange and similar documents due within 3 months of their issue date. Monetary assets also include the interest accrued on financial assets.

Financial assets payable or due within 3 months of the date of their receipt, issue, acquisition, or placement (deposits) are classified as cash and cash equivalents for the purposes of cash flow statement.

Cash is valued at the nominal value.

The interest received and due is classified as income from financial activities.

(f) Prepayments and accruals

i. Prepayments

Prepayments include the costs related to future periods occurring after the period in which they have been incurred. The timing and method of their recognition depend on the nature of the costs recognised, with taking into account the prudence principle.

ii. Accruals

Accruals are recognised at the amount of probable liabilities related to the current reporting period, in particular incurred in relation to:

- the provision of goods or services made for the undertaking by its business partners, where it is possible to estimate the amount of liability in a reliable manner,
- the obligation to provide goods or services relating to current operations in the future for unknown persons, where it is possible to estimate their amount in spite of the fact that the date when such liability arises is still unknown, including goods or services relating to repairs under guarantees and warranties for durable products sold.

The accruals are recognised corresponding to the passage of time/volume of goods or services. The timing and method of their recognition depend on the nature of the costs recognised, with taking into account the prudence principle

iii. Deferred income

Deferred income is recognised subject to the prudence principle and comprises in particular the following:

- amounts received or receivable from business partners in relation to goods or services to be provided in future reporting periods;
- cash and cash equivalents received for financing the acquisition or manufacture of fixed assets, including fixed assets under construction and development works if they do not increase equity under separate acts of law. Amounts recognised as deferred income are gradually released to other operating income, in parallel to accumulated amortisation and depreciation of fixed assets or costs of

development works financed from those sources;-value of fixed assets under construction, fixed assets and intangible assets received free of charge, including donations. Amounts recognised as deferred income are gradually released other operating income, in parallel to accumulated amortisation and depreciation of fixed assets or intangible assets;

-negative goodwill.

(g) Equity

Equity includes the initial capital, supplementary capital and capitals created by the company in accordance with the applicable law, articles of association and a resolution of the General Meeting of Shareholders, together with the amount resulting from the undistributed financial result brought forward.

The initial capital of the company is stated in the amount specified in the notarial deed and the entry into the commercial register at the nominal value.

Declared but not paid capital contributions are recognised as called-up initial capital.

Supplementary capital includes the capital from sale of shares at premium, other amounts in accordance with the effective legal regulations or notarial deed, and the amounts of the financial result transferred to the supplementary capital in accordance with the resolution of the General Meeting of Shareholders.

Undistributed financial result brought forward includes profits and losses from the preceding periods which have not been settled based on the resolutions of the General Meeting of Shareholders.

(h) Provisions for liabilities

Provisions for liabilities are valued at amounts which are reasonable and estimated in a reliable manner. The provisions are established for:

- certain or highly probable future liabilities whose amount can be estimated in a reliable manner, in particular for the losses incurred under ongoing business operations, including losses relative to granted guarantees, warranties, credit operations, the outcomes of pending court proceedings;
- future liabilities resulting from restructuring if an undertaking is obliged to restructure under separate regulations or if binding agreements have been concluded to that effect, and the restructuring plans allow for estimation of such future liabilities in a reliable manner.

The provisions are classified, as appropriate, as other operating costs, financial costs, or extraordinary losses, depending on circumstances to which future liabilities are related.

Provisions for employee benefits are charged to the costs of operating activities.

(i) Liabilities

Liabilities are classified as long-term liabilities if their maturity is more than one year as at the balance sheet date, and are classified as short-term liabilities if their maturity is less than one year as at the balance sheet date.

Long-term credits and loans are valued according to the adjusted acquisition price.

Liabilities are stated at the amounts due, that is together with the interest payable as at the balance sheet date. Such interest is charged to financial costs.

Assets used pursuant to financial leasing contracts are treated as the Company's assets and measured at their fair value as at the moment of acquisition thereof, not higher though than the present value of minimum lease payments. The resulting liability toward the lessor is stated in the balance sheet as a liability under financial leasing.

The lease payments are regarded separately as interest and principal part decreasing the liability under leasing so that the interest rate on the outstanding liability remains a fixed amount. Any related financial costs are charged directly to the profit and loss account.

Payments under operating leasing contracts are charged to the profit and loss account according to the straight-line method throughout the lease term, excluding the cases when other systematic basis for settlement is more representative for the temporal pattern governing the consumption of economic benefits arising from the lease of a given asset.

(j) Settlements with foreign entities

As at the balance sheet date, the assets and liabilities expressed in foreign currencies are recognised pursuant to the average rate of exchange effective at a given date and determined for a given currency by the National Bank of Poland.

During the financial year, the business operations expressed in foreign currencies and concerning the following items are recognised:

- cash, payment of receivables and settlement of liabilities - at the buying or selling rate of exchange of a bank whose services are used by the company;
- receivables and liabilities - at the average rate of exchange effective on the day preceding the day of performing the transaction determined for a given currency by the President of the National Bank of Poland, unless the customs clearance proof sets different rate of exchange.

Foreign exchange gains and losses arising upon payment and as at the balance sheet date are recognised in financial costs and income, and in justified cases - in the costs of product manufacture or the acquisition price for goods, and also the acquisition price or costs of manufacture of tangible fixed assets, fixed assets under construction or intangible assets.

(k) Revenue from sales

The revenue from sales is recognised upon the delivery of goods or the provision of services. The sale is stated in the net value, i.e. without taking into account the tax on goods and services and any granted discounts.

(l) Mandatory charges on the financial result

Mandatory charges on the financial result include corporate income tax (pursuant to the Corporate Income Tax Act) and other equivalent charges under separate regulations.

Income tax is calculated on the basis of the gross profit determined pursuant to the accounting regulations, adjusted for non-taxable income, costs not being tax deductible expenses, and deductions of losses brought forward, investment allowances and donations.

The undertaking establishes the provisions and identifies the deferred income tax assets in connection with the temporary differences between the book value of assets and liabilities and their tax value and the tax loss deductible in the future. Deferred income tax assets are determined in the amount which will presumably be deducted in the future from the income tax with respect to

negative temporary differences which will reduce income tax base in the future as well as the deductible tax loss, determined pursuant to the prudence principle.

The Company determines the deferred income tax assets with respect to all negative temporary differences and with respect to tax loss deductible in the future and simultaneously makes the revaluation write-offs for these assets.

The provision for the deferred income tax is established in the amount of the income tax to be paid in the future with respect to positive temporary differences, i.e. the differences which will increase the income tax base in the future.

The amount of the deferred income tax provision and assets is estimated at income tax rates applicable in the year when the tax liability arises.

The difference between the amount of the deferred income tax provisions and assets at the beginning and at the end of the reporting period influences the financial result but the deferred income tax provisions and assets relating to the operations settled with the equity are also posted to the equity.

The temporary differences include but are not limited to provisions, tax losses brought forward whose settlement is likely, and unrealised foreign exchange gains/losses.

If the temporary differences arise in different periods and are reversed in the periods in which tax rates stipulated in tax regulations are different, then the deferred income tax provisions and assets are estimated on the assumption that the temporary differences arising earlier are reversed as the first ones.

The undertaking assumed the principle that the deferred income tax assets and provisions are not offset.

11. Average exchange rates of PLN to EUR

In the period covered by the financial statements and in the comparable period, the average exchange rates of PLN to EUR determined by the National Bank of Poland were as follows:

Financial period	Average exchange rate in the period (1)	Minimum exchange rate in the period	Maximum exchange rate in the period	Exchange rate as at the last day in the period
01.01 - 31.12.2013	4.2110	4.0671	4.3432	4.1472
01.01 - 31.12.2012	4.1736	4.0465	4.5135	4.0882

(1) The average of the exchange rates applicable on the last day of each month in a given period

The basic items in the balance sheet, profit and loss account, and cash flow statement were converted into EUR pursuant to the defined applicable principle of conversion:

- the balance sheet - according to the exchange rate effective on the last day of a relevant period,
- the profit and loss account and the cash flow statement - according to the average exchange rates in a relevant period calculated as the arithmetic mean of the exchange rates applicable on the last day of each month in a given period.

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

The conversion was made in accordance with the exchange rates specified hereinabove through dividing the values expressed in PLN thousand by the exchange rate.

12. Selected financial data of the Company converted into EUR

Period from 01.01 - 31.12.2013	PLN thousand	EUR thousand
Net revenue from sales of products, goods and materials	199,760	47,438
Profit (loss) on operating activities	3,535	839
Gross profit (loss)	925	220
Net profit /loss	467	111
Total assets	107,552	25,934
Fixed assets	93,393	22,520
Current assets	14,159	3,414
Equity	44,628	10,761
Share capital	23,567	5,683
Total liabilities	62,924	15,173
- of which: short-term liabilities	33,524	8,084
Number of shares (pcs)	23,566,900	23,566,900
Book value per one share (in PLN/EUR)	1.89	0.46
Net profit (loss) per one share (in PLN/EUR)	0.02	0.00
Net cash flows from operating activities	17,451	4,144
Net cash flows from investing activities	-2,285	-543
Net cash flows from financing activities	-15,195	-3,608
Change in cash and cash equivalents	-29	-7

Period from 01.01 - 31.12.2012	PLN thousand	EUR thousand
Net revenue from sales of products, goods and materials	180,785	43,316
Profit (loss) on operating activities	-7,366	-1,765
Gross profit (loss)	-9,971	-2,389
Net profit /loss	-8,831	-2,116
Total assets	118,780	29,054
Fixed assets	104,127	25,470
Current assets	14,653	3,584
Equity	44,161	10,802
Share capital	23,567	5,765
Total liabilities	74,619	18,252
- of which: short-term liabilities	39,738	9,720

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Number of shares (pcs)	23,566,900	23,566,900
Book value per one share (in PLN/EUR)	1.87	0.46
Net profit (loss) per one share (in PLN/EUR)	-0.37	-0.09
Net cash flows from operating activities	11,052	2,648
Net cash flows from investing activities	-14,547	-3,485
Net cash flows from financing activities	-622	-149
Change in cash and cash equivalents	-4,117	-986

13. Differences between Polish and international accounting standards

The undertaking draws up its financial statements pursuant to the Polish accounting standards.

FINANCIAL STATEMENTS of Centrum Medyczne Enel-Med S.A.

Financial statements of the Company for the period from January 1, 2013, to December 31, 2013, and comparable financial data for the analogous period in the preceding year.

Balance sheet

ASSETS	Note	31.12.2013	31.12.2012
I. Fixed assets		93,393	104,127
1. Intangible assets, of which:	1	1,510	1,858
- goodwill			
2. Tangible fixed assets	2	83,996	94,610
3. Long-term receivables	3, 8	580	581
3.1. Amounts due from related undertakings			
3.2. Amounts due from other undertakings		580	581
4. Long-term investments	4	4,701	4,741
4.1. Immovable property			
4.2. Intangible assets			
4.3. Long-term financial assets		4,701	4,741
a) in related undertakings, of which:		650	640
- shares in subordinated undertakings valued using the equity method		650	640
b) in other undertakings		4,051	4,101
4.4. Other long-term investments			
5. Long-term prepayments and accruals	5	2,606	2,337
5.1. Deferred income tax assets		2,606	2,337
5.2. Other prepayments and accruals			
II. Current assets		14,159	14,653
1. Inventories	6	973	1,005
2. Short-term receivables	7, 8	11,335	11,139
2.1. Amounts due from related undertakings		5	1
2.2. Amounts due from other undertakings		11,330	11,138
3. Short-term investments	9	381	409
3.1. Short-term financial assets		381	409
a) in related undertakings			
b) in other undertakings			
c) cash and other monetary assets		381	409
3.2. Other short-term investments			

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

4. Short-term prepayments and accruals	10	1,470	2,100
Total assets		107,552	118,780

LIABILITIES	Note	31.12.2013	31.12.2012
I. Equity		44,628	44,161
1. Initial capital	12	23,567	23,567
2. Called-up initial capital (negative figure)			
3. Own shares (negative figure)	13		
4. Supplementary capital	14	29,992	29,992
5. Revaluation reserve	15		
6. Other reserve capitals	16		
7. Profits (losses) brought forward		-9,398	-567
8. Net profit (loss)	35	467	-8,831
9. Write-offs from net profit during the financial year	17		
II. Liabilities and provisions for liabilities		62,924	74,619
1. Provisions for liabilities	18	2,980	2,162
1.1. Deferred income tax provision		2,164	1,488
1.2. Provision for pensions and similar benefits		781	640
a) long-term		189	170
b) short-term		592	470
1.3. Other provisions		34	34
a) long-term			
b) short-term		34	34
2. Long-term liabilities	19	26,159	32,436
2.1. Amounts due to related undertakings			
2.2. Amounts due to other undertakings		26,159	32,436
3. Short-term liabilities	20	33,524	39,738
3.1. Amounts due to related undertakings			635
3.2. Amounts due to other undertakings		33,459	39,087
3.3. Special funds		65	16
4. Accruals	21	261	284
4.1. Negative goodwill			
4.2. Other accruals		261	284
a) long-term		110	12

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

b) short-term		152	271
Total liabilities		107,552	118,780

Book value (in PLN thousand)		44,628	44,161
Number of shares (pcs)		23,566,900	23,566,900
Book value per one share (in PLN)	22	1.89	1.87
Diluted number of shares (pcs)		23,566,900	23,566,900
Diluted book value per one share (in PLN)	22	1.89	1.87

Off-balance-sheet items

	Note	31.12.2013	31.12.2012
1. Contingent receivables		0	0
1.1. Amounts due from related undertakings	23	0	0
1.2. Amounts due from other undertakings		0	0
2. Contingent liabilities		15,711	15,062
2.1. Due to related undertakings	23		
2.2. Due to other undertakings (on account of)		15,711	15,062
Bank guarantees granted by Credit Agricole Bank Polska S.A. being the performance bonds		0	3,639
Promissory note collateral for promissory notes issued by Centrum Medyczne Enel-Med Sp. z o. o. to secure the liabilities arising from leases towards BFL Nieruchomości Sp. z o. o.		8,934	9,373
Bank guarantees granted by Millennium Bank Polska S.A. being the performance bonds		5,430	0
Court cases pending against the Company		1,348	2,050
3. Other		0	0
Total off-balance-sheet items		15,062	15,062

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Profit and loss account

	Note	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
I. Net revenue from sales of products, goods and materials, of which		199,760	180,785
- from related undertakings			
1. Net revenue from sales of products	24	199,760	180,785
2. Net revenue from sales of goods and materials	25		
II. Cost of products, goods and materials sold, of which	26	184,586	175,302
- to related undertakings			
1. Manufacturing costs of products sold		184,586	175,302
2. Value of goods and materials sold			
III. Gross profit (loss) on sales (I - II)		15,173	5,483
IV. Costs of sale	26	6,974	6,805
V. Overheads	26	6,048	6,433
VI. Profit (loss) on sales (III-IV-V)		2,152	-7,755
VII. Other operating income	27	1,738	1,003
1. Profit on sale of non-financial fixed assets		120	88
2. Subsidies		244	196
3. Other operating income		1,374	719
VIII. Other operating costs	28	355	614
1. Loss on sale of non-financial fixed assets			
2. Revaluation of non-financial assets			147
3. Other operating costs		355	467
IX. Profit (loss) on operating activities (VI+VII-VIII)		3,535	-7,366
X. Financial income	29	175	293
1. Dividends and profit sharing, of which:			
- from related undertakings			
2. Interest, of which:		175	293
- from related undertakings			
3. Profit on sale of investments			
4. Revaluation of investments			
5. Other			
XI. Financial costs	30	2,784	2,898
1. Interest, of which:		2,727	2,795

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

- to related undertakings			
2. Loss on sale of investments			
3. Revaluation of investments			
4. Other		58	103
XII. Profit (loss) on business activities (IX+X-XI)		925	-9,971
XIII. J. Result of extraordinary events (XIII.1. - XIII2.)			
1. Extraordinary profits	31		
2. Extraordinary losses	32		
XIV. Gross profit (loss) (XII+/-XIII)		925	-9,971
XV. Income tax	33	458	-1,140
a) current part		51	16
b) deferred part		407	-1,156
XVI. Other obligatory reductions of profit (increases of loss)	34		
XVII. Share in net profit (loss) of subordinated undertakings valued using the equity method			
XVIII. Net profit (loss) (XIV-XV-XVI+/-XVI)		467	-8,831

Net profit (loss) (annualised)		467	-8,831
Weighted average number of ordinary shares (pcs)		23,566,900	23,566,900
Profit (loss) per one ordinary share (in PLN)	36	0.02	-0.37
Diluted weighted average number of ordinary shares (pcs)		23,566,900	23,566,900
Diluted profit (loss) per one ordinary share (in PLN)		0.02	-0.37

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Funds flow statement

	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
I. Equity at the beginning of the Period (OB)	49,612	53,699
a) amendments to the adopted accounting principles (policy)		
b) adjustments for errors		
I.a Equity at the beginning of the period (OB), after reconciliation to comparable data	49,612	53,699
1. Initial capital at the beginning of the period	23,567	23,567
1.1. Changes in initial capital		
a) increase (as a result of)		
- issue of shares		
b) decrease		
1.2. Initial capital at the end of the period	23,567	23,567
2. Called-up initial capital at the beginning of the period		
2.1. Changes in called-up initial capital		
a) increase		
b) decrease		
2.2. Called-up initial capital at the end of the period		
3. Own shares at the beginning of the period		
3.1. Changes in own shares		
a) increase		
b) decrease		
3.2. Own shares at the end of the period		
4. Supplementary capital at the beginning of the period	29,991	26,611
4.1. Changes in supplementary capital		
a) increase (as a result of)		3,380
- issue of shares at premium		
- distribution of profits (statutory)		3,380
b) decrease (as a result of)		
- expenses relative to stock exchange listing		
4.2. Supplementary capital at the end of the period	29,991	29,991
5. Revaluation reserve at the beginning of the period		
- amendments to the adopted accounting principles (policy)		
5.1. Changes in revaluation reserve		

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

a) increase		
b) decrease		
5.2. Revaluation reserve at the end of the period		
6. Other reserve capitals at the beginning of the period		
6.1. Changes in other reserve capitals		
a) increase (as a result of)		
- payments to increase the initial capital not registered in the National Court Register		
b) decrease		
- payments towards the initial capital registered in the National Court Register		
6.2. Other reserve capitals at the end of the period		
7. Profit (loss) brought forward at the beginning of the period	-566	3,521
7.1. Profit brought forward at the beginning of the period	0	969
a) amendments to the adopted accounting principles (policy)		
b) adjustments for errors		
7.2. Profit brought forward at the beginning of the period, after reconciliation to comparable data	0	4,087
a) increase (as a result of)		
- distribution of profit brought forward		
b) decrease (as a result of)		4,087
- reclassification to supplementary capital		3,380
- dividends paid		707
7.3. Profit brought forward at the end of the period	0	0
7.4. Loss brought forward at the beginning of the period	-566	-566
a) amendments to the adopted accounting principles (policy)		
b) adjustments for errors		
7.5. Loss brought forward at the beginning of the period, after reconciliation to comparable data	-566	-566
a) increase (as a result of)	-8,831	
reclassification of loss brought forward to be covered	-8,831	
b) decrease (as a result of)		
- coverage of loss from supplementary capital		
7.6. Loss brought forward at the end of the period	-9,398	-566
7.7. Profit (loss) brought forward at the end of the period	-9,398	-566
8. Net result	467	-8,831

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.**(All amounts are stated in PLN thousand unless otherwise indicated)**

a) net profit	467	
b) net loss		-8,831
c) adjustments for errors (loss)		
Equity at the end of the period (CB)	44,628	44,161
III. Equity after adjustments for the proposed distribution of profit (coverage of loss)	44,628	44,161

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Cash flow statement - indirect method

	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
A. Cash flows from operating activities		
I. Net profit (loss)	467	-8,831
II. Total adjustments	16,983	19,883
1. Amortisation and depreciation	14,107	14,460
2. Foreign exchange gains (losses)		
3. Interest and profit sharing (dividends)	2,460	2,460
4. Profit (loss) on investing activities	-120	-88
5. Change in provisions	818	777
6. Change in inventories	32	-43
7. Change in receivables	-195	-191
8. Change in short-term liabilities, with the exception of loans and credits	-235	2,847
9. Change in prepayments and accruals	338	-78
10. Other adjustments	-221	-259
III. Net cash flows from operating activities (I+/-II)	17,451	11,052
I. Inflows	359	4,011
1. Sale of intangible assets and tangible fixed assets	359	4,011
2. Sale of investments in immovable property and intangible assets		
3. From financial assets, of which:		
a) in related undertakings		
b) in other undertakings		
4. Other investment inflows		
II. Outflows	2,644	18,558
1. Purchase of intangible assets and tangible fixed assets	2,634	18,558
2. Investments in immovable property and intangible assets		
3. On financial assets, of which:	10	
a) in related undertakings	10	
- purchase of financial assets	10	
- long term loans		
b) in other undertakings		
- purchase of financial assets		

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

- long term loans		
4. Other investment outflows		
III. Net cash flows from investing activities (I - II)	-2,285	-14,547
C. Cash flows from financial activities		
I. Inflows	11,598	17,357
1. Net inflows from issue of shares and other equity instruments and additional contributions to equity		
2. Credits and loans	11,368	17,166
3. Issue of debt securities		
4. Other financial inflows	231	191
II. Outflows	26,793	17,979
1. Purchase of own shares		
2. Dividends and other payments to shareholders		707
3. Outflows under distribution of profit other than payments to shareholders		
4. Repayment of credits and loans	21,653	13,824
5. Redemption of debt securities		
6. Other financial liabilities		
7. Payments under financial lease contracts	2,367	1,198
8. Interest	2,773	2,250
9. Other financial outflows		
III. Net cash flows from financial activities (I - II)	-15,195	-622
D. Total net cash flows (A.III+/-B.III+/-C.III)	-29	-4,117
E. Balance sheet change in cash and cash equivalents, of which:	-29	-4,117
change in cash and cash equivalents due to foreign exchange gains/losses		
F. Cash and cash equivalents at the beginning of the period	409	4,526
G. Cash and cash equivalents at the end of the period (F+/-D), of which:	381	409
- not fully disposable		

NOTES TO THE FINANCIAL STATEMENTS

NOTE 1

INTANGIBLE ASSETS	31.12.2013	31.12.2012
a) costs of research and development		
b) goodwill		
c) acquired concessions, patents, licences and similar assets, of which:		
- computer software		
d) other intangible assets	1,510	1,858
e) advances on intangible assets		
Total intangible assets	1,510	158

INTANGIBLE ASSETS (OWNERSHIP STRUCTURE)	31.12.2013	31.12.2012
a) company-owned	1,395	1,645
b) used pursuant to rent, tenancy or another agreement, including lease agreement	115	213
Total intangible assets	1,510	1,858

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

CHANGES IN INTANGIBLE ASSETS (BY NATURE)	costs of research and development	goodwill	acquired patents, licences and similar assets, of which:	concessions,	other intangible assets	advances on intangible assets	Total intangible assets
				computer software			
31.12.2013							
a) gross value of intangible assets at the beginning of the period		131			4,429		4,560
b) increase (as a result of)					170		170
purchase					53		53
settlement of intangible assets under construction					117		117
c) decrease					25		25
liquidation					25		25
d) gross value of intangible assets at the end of the period		131			4,574		4,705
e) accumulated amortisation (depreciation) at the beginning of the period		131			2,571		2,702
f) amortisation for the period (on account of)					493		493
wear and tear					518		518
liquidation					-25		-25
g) accumulated amortisation (depreciation) at the end of the period		131			3,064		3,195
h) impairment write-downs at the beginning of the period							
i) impairment write-downs at the end of the period							
j) net value of intangible assets at the end of the period		0			1,510		1,510

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

CHANGES IN INTANGIBLE ASSETS (BY NATURE)	costs of research and development	goodwill	acquired patents, assets,	concessions, licences and similar of which:	other intangible assets	advances on intangible assets	Total intangible assets
31.12.2012							
a) gross value of intangible assets at the beginning of the period		131			3,902		4,033
b) increase (as a result of)					542		542
purchase					377		377
settlement of intangible assets under construction					165		165
c) decrease					15		15
liquidation					15		15
d) gross value of intangible assets at the end of the period		131			4,429		4,560
e) accumulated amortisation (depreciation) at the beginning of the period		131			2,114		2,245
f) amortisation for the period (on account of)					457		457
wear and tear					459		459
liquidation					-2		-2
g) accumulated amortisation (depreciation) at the end of the period		131			2,571		2,702
h) impairment write-downs at the beginning of the period							
i) impairment write-downs at the end of the period							
j) net value of intangible assets at the end of the period		0			1,858		1,858

NOTE 2

TANGIBLE FIXED ASSETS	31.12.2013	31.12.2012
a) fixed assets, of which:	82,291	93,485
- land (of which: perpetual usufruct of land)	519	519
- buildings, premises and civil engineering structures	5,614	5,895
- plant and machinery	3,473	4,339
- means of transportation	1,242	351
- other fixed assets	71,442	82,381
b) fixed assets under construction	1,705	1,125
c) advances on fixed assets under construction		
Total tangible fixed assets	83,996	94,610

BALANCE-SHEET TANGIBLE FIXED ASSETS (OWNERSHIP STRUCTURE)	31.12.2013	31.12.2012
a) company-owned	75,787	86,394
b) used pursuant to rent, tenancy or another agreement, including lease agreement, of which:	6,504	7,091
leasing	6,504	7,091
Total balance-sheet tangible fixed assets	82,291	93,485

OFF-BALANCE-SHEET TANGIBLE FIXED ASSETS	31.12.2013	31.12.2012
- used pursuant to rent, tenancy or another agreement, including lease agreement, of which:	1,864	2,669
operating lease agreements	1,864	2,669
Total off-balance-sheet tangible fixed assets	1,864	2,669

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

CHANGES IN FIXED ASSETS (BY NATURE)	land (of which: perpetual usufruct of land)	buildings, premises and civil engineering structures	plant and machinery	means of transportation	other fixed assets	Total fixed assets
31.12.2013						
a) gross value of fixed assets at the beginning of the period	519	7,559	8,229	959	124,927	142,193
b) increase (as a result of)		9	393	998	1,233	2,633
purchase		9	238	371	636	1,254
settlement of fixed assets under construction			155	627	597	1,379
c) decrease (as a result of)			217	10	3,655	3,882
sale				10	3,127	3,137
liquidation			217		528	745
d) gross value of fixed assets at the end of the period	519	7,568	8,405	1,947	122,505	140,944
e) accumulated amortisation (depreciation) at the beginning of the period		1,664	3,890	608	42,546	48,708
f) amortisation for the period (on account of)		290	1,042	97	8,517	9,946
wear and tear		290	1,259	107	11,932	13,588
sale				-10	-2,935	-2,945
liquidation			-217		-480	-697
g) accumulated amortisation (depreciation) at the end of the period		1,954	4,931	705	51,063	58,653
h) impairment write-downs at the beginning of the period						
- increase						
- decrease						
i) impairment write-downs at the end of the period						
j) net value of fixed assets at the end of the period	519	5,614	3,473	1,242	71,442	82,291

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

CHANGES IN FIXED ASSETS (BY NATURE)	land (of which: perpetual usufruct of land)	buildings, premises and civil engineering structures	plant and machinery	means of transportation	other fixed assets	Total fixed assets
31.12.2012						
a) gross value of fixed assets at the beginning of the period	519	7,543	6,970	1,262	97,520	113,814
b) increase (as a result of)		16	1,795	200	31,308	33,319
purchase		16	842	200	9,071	10,129
settlement of fixed assets under construction			953		22,237	23,190
c) decrease (as a result of)			536	503	3,901	4,940
sale			536	503	3,829	4,868
liquidation					72	72
d) gross value of fixed assets at the end of the period	519	7,559	8,229	959	124,927	142,193
e) accumulated amortisation (depreciation) at the beginning of the period		1,372	2,604	785	30,762	35,523
f) amortisation for the period (on account of)		292	1,286	-177	11,784	13,185
wear and tear		292	1,357	222	12,130	14,001
sale			-71	-399	-276	-746
liquidation					-70	-70
g) accumulated amortisation (depreciation) at the end of the period		1,664	3,890	608	42,546	48,708
h) impairment write-downs at the beginning of the period						
- increase						
- decrease						
i) impairment write-downs at the end of the period						
j) net value of fixed assets at the end of the period	519	5,895	4,339	351	82,381	93,485

NOTE 3

LONG-TERM RECEIVABLES	31.12.2013	31.12.2012
a) from related undertakings		
b) from other undertakings (on account of)	580	581
- deposits	580	581
Net long-term receivables	580	581
c) receivables revaluation write-offs		
Gross long-term receivables	580	581

CHANGE IN LONG-TERM RECEIVABLES (ON ACCOUNT OF)	31.12.2013	31.12.2012
a) at the beginning of the period	581	1,038
deposits		
b) increase (as a result of)		
deposits		
c) decrease (as a result of)	1	457
deposits	1	457
d) at the end of the period	580	581
deposits	580	581

CHANGE IN REVALUATION WRITE-OFFS FOR LONG-TERM RECEIVABLES	31.12.2013	31.12.2012
At the beginning of the period	0	0
a) increase	0	0
b) decrease	0	0
Revaluation writ-offs for long-term receivables at the end of the period	0	0

LONG-TERM RECEIVABLES (BY CURRENCY)	31.12.2013	31.12.2012
a) in Polish currency	580	581
b) in foreign currencies (acc. to currency and after conversion into PLN)		
Total long-term receivables	580	581

NOTE 4

LONG-TERM FINANCIAL ASSETS	31.12.2013	31.12.2012
a) in subsidiaries	650	640

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

- shares	650	640
b) in co-subsiaries		
c) in affiliated undertakings		
d) in significant investor		
e) in partner of co-subsiary		
f) in parent entity		
g) in other undertakings	4,051	4,101
- shares		
- debt securities		
- other securities		
- loans	4,051	4,101
other long-term financial assets		
Total long-term financial assets	4,701	4,741

CHANGE IN LONG-TERM FINANCIAL ASSETS	31.12.2013	31.12.2012
(BY NATURE)		
a) at the beginning of the period	4,741	4,474
- loans	640	3,834
- shares	4,101	640
b) increase (as a result of)	177	267
- interest calculated on loans	167	267
- loans		
- shares	10	
c) decrease	216	
- valuation acc. to IRR	216	
d) at the end of the period	4,701	4,741
- shares	650	640
- loans	4,051	4,101

SHARES IN SUBORDINATED UNDERTAKINGS

A	b	c	d	e	f	g	h	i	j	k	l
name (business name) of an undertaking with legal form	registered office	objectives of enterprise	nature of relationship (subsidiary, co-subsidiary, affiliated undertaking, with indication of direct and indirect relationships)	applied method of consolidation/valuation using the equity method, or indication that an undertaking is not subject to consolidation/valuation using the equity method	date of assuming control, co-control/ acquiring substantial influence	value of shares acc. to acquisition price	revaluation adjustments (total)	balance-sheet value of shares	percent of held initial capital	share in total number of votes at the general meeting	indication of grounds for control/ co-control/ substantial influence other than specified in j) or k)
Enelbud Sp. z o.o	Warsaw		subsidiary	not subject to consolidation acc. to Art. 58 of the Acc. Act	30.09.2011	640		640	80%	80%	
Centrum Medyczne Diagnostyka Sp. z o.o.	Warsaw		subsidiary	not subject to consolidation acc. to Art. 58 of the Acc. Act	03.09.2013	5		5	100%	100%	
Centrum Medyczne Diagnostyka Obrazowa Sp. z o.o.	Warsaw		subsidiary	not subject to consolidation acc. to Art. 58 of the Acc. Act	02.12.2013	5		5	100%	100%	
Bonus Vitae Sp. z o.o.	Warsaw		affiliated undertaking	not subject to consolidation acc. to Art. 58 of the Acc. Act					40%	40%	through Enelbud Sp.z.o.o.
TOTAL						650		650			

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

	m						n			o		p	r	s	t
name (business name) of an undertaking with legal form	equity of an undertaking, of which:						liabilities and provisions for liabilities of an undertaking, of which:			receivables of an undertaking:		total assets of an undertaking	revenue from sales	value of shares in an undertaking not paid by the issuer	received or due dividend from an undertaking for the last financial year
	initial capital	called-up initial capital (negative figure)	Supplementary capital	other equity, of which			Total	long-term liabilities	short-term liabilities	long-term receivables	short-term receivables				
				Total remaining equity	Profits (losses) brought forward	net profit (loss)									
Enelbud Sp. z o.o.	50		160	2,124	-476	957	3,173		3,158		4,457	5,989	6,954		
Centrum Medyczne Diagnostyka Sp. z o.o.	5					-5	12		12			12			
Centrum Medyczne Diagnostyka Obrazowa Sp. z o.o.	5					-1	1		1			5			
Bonus Vitae Sp. z o.o.	5											5			
TOTAL	60	0	160	2,124	-476	951	3,186	0	3,171	0	4,457	6,011	6,954	0	0

SHARES IN OTHER UNDERTAKINGS

The Company does not hold any shares in other undertakings.

SECURITIES, SHARES, AND OTHER LONG-TERM FINANCIAL ASSETS (BY TRANSFERABILITY)	31.12.2013	31.12.2012
A. With unrestricted transferability, listed on stock exchanges (balance-sheet value)		
B. With unrestricted transferability, listed on OTC markets (balance-sheet value)		
C. With unrestricted transferability, not listed on regulated market (balance-sheet value)		
D. With restricted transferability (balance-sheet value)	4,701	4,741
a) shares (balance-sheet value):	650	640
- revaluation adjustments (for the period)		
- value at the beginning of the period		
- value acc. to acquisition prices		
b) bonds (balance-sheet value)		
- revaluation adjustments (for the period)		
- value at the beginning of the period		
- value acc. to acquisition prices		
c) other - by nature groups (balance-sheet value):	4,051	4,101
- revaluation adjustments (for the period)		
- value at the beginning of the period		
- value acc. to acquisition prices		
Total value acc. to acquisition prices	4,701	4,741
Total value at the beginning of the period	4,741	4,474
Total revaluation adjustments (for the period)		
Total balance-sheet value	4,701	4,741

GRANTED LONG-TERM LOANS (BY CURRENCY)	31.12.2013	31.12.2012
a) in Polish currency	4,051	4,101
b) in foreign currencies (acc. to currency and after conversion into PLN)		
Total granted long-term loans	4,051	4,101

NOTE 5

CHANGE IN DEFERRED INCOME TAX ASSETS	31.12.2013	31.12.2012
1. 1. Deferred income tax assets at the beginning of the period, of which:	2,337	541
a) related to financial result	2,337	541
unpaid wages and salaries and contributions to the Social Insurance Institution	291	276
provisions for unused holidays	88	71
provisions for retirement benefits	34	25
unpaid accrued interest	14	8
receivables revaluation write-off	181	153
other provisions	118	2
provision for auditing the financial statements	7	6
difference on leaseback	38	
tax loss	1,566	
b) related to equity		
c) related to goodwill or negative goodwill		
2. Increases	377	1,796
a) related to financial result for the period with respect to negative temporary differences (as a result of)	104	230
unpaid wages and salaries and contributions to the Social Insurance Institution	12	16
provisions for unused holidays	24	17
provisions for retirement benefits	3	9
unpaid invoices to CIT	4	
unpaid accrued interest		6
receivables revaluation write-off		28
other provisions		115
difference on profit from leaseback		38
valuation of loans acc. to IRR	60	
provision for auditing the financial statements		1
b) related to financial result for the period with respect to tax loss (as a result of)	274	1,566
tax loss	274	1,566
c) related to equity with respect to negative temporary differences		

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

d) related to equity with respect to tax loss		
e) related to goodwill or negative goodwill with respect to negative temporary differences		
3. Decreases	108	
a) related to financial result for the period with respect to negative temporary differences (as a result of)	108	
receivables revaluation write-off	17	
difference on profit from leaseback	11	
other provisions	80	
b) related to financial result for the period with respect to tax loss		
c) related to equity with respect to negative temporary differences		
d) related to equity with respect to tax loss		
e) related to goodwill or negative goodwill with respect to negative temporary differences		
4. Total deferred income tax assets at the end of the period, of which:	2,606	2,337
a) related to financial result	2,606	2,337
unpaid wages and salaries and contributions to the Social Insurance Institution	304	291
provisions for unused holidays	111	88
provisions for retirement benefits	37	34
unpaid accrued interest	14	14
receivables revaluation write-off	164	181
other provisions	37	118
provision for auditing the financial statements	7	7
difference on profit from leaseback	28	38
valuation of loans acc. to IRR	61	
unpaid invoices to CIT	4	
tax loss	1,839	1,566
b) related to equity		
c) related to goodwill or negative goodwill		

Negative temporary differences	Expiry date	31.12.2013	31.12.2012
I. ASSETS			
receivables revaluation write-off	next financial year	863	954

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

valuation of loans acc. to IRR	next financial year	216	
II. LIABILITIES			
unpaid wages and salaries and contributions to the Social Insurance Institution	next financial year	1,599	1,534
provisions for unused holidays	next financial year	586	461
other provisions	next financial year	196	619
difference on profit from leaseback	31.12.2016	146	201
tax loss	31.12.2018	9,681	8,242
unpaid accrued interest	31.12.2013	72	74
provisions for retirement benefits	next financial year	195	179
valuation of loans acc. to IRR	next financial year	103	
unpaid invoices to CIT	next financial year	25	
provision for auditing the financial statements	next financial year	34	34
Total		13,717	12,298

NOTE 6

INVENTORIES	31.12.2013	31.12.2012
a) materials	973	1,005
b) semi-finished products and work in progress		
c) finished products		
d) goods		
e) advances on supplies		
Total inventories	973	1,005

NOTE 7

SHORT-TERM RECEIVABLES	31.12.2013	31.12.2012
a) from related undertakings	5	1
- trade receivables with a maturity of	5	1
- up to 12 months	5	1
- over 12 months		
- receivables under litigation		
- other		
b) amounts due from other undertakings	11,330	11,138

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

- trade receivables with a maturity of	11,268	10,957
- up to 12 months	11,268	10,957
- over 12 months		
- receivables relative to taxes, subsidies, customs duties, social and health insurance, and other benefits		24
- receivables under litigation		
- other	62	157
Total net short-term receivables	11,335	11,139
c) receivables revaluation write-offs	863	954
Total gross short-term receivables	12,199	12,093

SHORT-TERM RECEIVABLES FROM RELATED UNDERTAKINGS	31.12.2013	31.12.2012
a) trade receivables, of which:	5	1
- from subsidiaries	5	1
b) other		
c) receivables under litigation		
Total net short-term receivables from related undertakings	5	1
d) revaluation write-offs for receivables from related undertakings		
Total gross short-term receivables from related undertakings	5	1

CHANGE IN REVALUATION WRITE-OFFS FOR SHORT-TERM RECEIVABLES	31.12.2013	31.12.2012
At the beginning of the period	954	807
a) increase (as a result of)		147
revaluation write-off created		147
b) decrease (as a result of)	90	
revaluation write-off released	90	
Revaluation write-offs for short-term receivables at the end of the period	863	954

GROSS SHORT-TERM RECEIVABLES (BY CURRENCY)	31.12.2013	31.12.2012
a) in Polish currency	12,199	12,093
b) in foreign currencies (acc. to currency and after conversion into PLN)		
Total short-term receivables	12,199	12,093

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

(GROSS) TRADE RECEIVABLES WITH THE FOLLOWING MATURITY AS AT THE BALANCE SHEET DATE:	31.12.2013	31.12.2012
a) up to 1 month	8,292	7,419
b) between 1 month and 3 months		
c) between 3 months and 6 months		
d) between 6 months and 12 months		
e) over 12 months		
f) overdue receivables	3,845	4,493
Total trade receivables (gross)	12,137	11,912
g) trade receivables revaluation write-offs	863	954
Total trade receivables (net)	11,273	10,958

(GROSS) OVERDUE TRADE RECEIVABLES BROKEN DOWN INTO RECEIVABLES NOT REPAYED IN THE PERIOD OF:	31.12.2013	31.12.2012
a) up to 1 month	2,344	2,979
b) between 1 month and 3 months	467	420
c) between 3 months and 6 months	85	32
d) between 6 months and 12 months	81	175
e) over 12 months	867	887
Total overdue trade receivables (gross)	3,845	4,493
f) overdue trade receivables revaluation write-offs	863	954
Total overdue trade receivables (net)	2,981	3,539

NOTE 8

TOTAL VALUE OF OVERDUE RECEIVABLES	31.12.2013	31.12.2012
Gross overdue receivables	3,845	4,493
- of which: gross disputable receivables		
a) gross trade receivables	3,845	4,493
b) gross other receivables		
c) gross receivables under litigation		
Overdue receivables revaluation write-offs	863	954
- of which: disputable receivables revaluation write-offs		
Net overdue receivables	2,981	3,539
~ of which: net disputable receivables		

NOTE 9

SHORT-TERM FINANCIAL ASSETS	31.12.2013	31.12.2012
a) in subsidiaries		
b) in co-subsidiaries		
c) in affiliated undertakings		
d) in significant investor		
e) in partner of co-subsidiary		
f) in parent entity		
g) in other undertakings		
h) cash and other monetary assets	381	409
- cash in hand and at bank	74	66
- other cash and cash equivalents	307	343
- other monetary assets		
Total short-term financial assets	381	409

CASH AND OTHER MONETARY ASSETS (BY CURRENCY)	31.12.2013	31.12.2012
a) in Polish currency	381	409
b) in foreign currencies (acc. to currency and after conversion into PLN)		
Total cash and other monetary assets	381	409

NOTE 10

SHORT-TERM PREPAYMENTS	31.12.2013	31.12.2012
a) prepayments, of which:	1,069	916
costs with respect to January next year	449	372
insurance	349	388
standing charges and licences	39	35
service costs	99	42
subscription	1	2
advisory services		4
advertising services (banners)		2
publication in multi-media package	38	5
fees for occupation of roadway	11	15
equipment concerning investment under construction	37	15
fee for transfer of ownership of EFL	21	27

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

fees for membership	4	4
hosting and Internet domains	3	5
other	18	
b) other prepayments, of which:	401	1,184
revenues from the National Health Fund not invoiced as at the balance sheet date	401	1,184
Total short-term prepayments	1,470	2,100

NOTE 11

INFORMATION CONCERNING REVALUATION WRITE-OFFS FOR MAIN ASSETS	31.12.2013	31.12.2012
a) Amount of receivables revaluation write-offs (as a result of)		
receivables becoming overdue	863	954
Total amount of overdue receivables revaluation write-offs, of which:	863	954
- related directly to equity		
Total revaluation write-offs for main assets, of which:	863	954
- related directly to equity		
a) amount of reversal of receivables revaluation write-offs (as a result of)		
overdue receivables		
Total amount of reversal of overdue receivables revaluation write-offs, of which:		
- related directly to equity		
Total reversal of revaluation write-offs for main assets, of which:		
- related directly to equity		

NOTE 12

INITIAL CAPITAL (STRUCTURE)

Series/issue	Type of share	Type of share privilege	Type of restriction of rights to shares	Number of shares	Nominal value of series/issue	Manner of capital coverage	Registration date	Right to dividend (from [date])
A	bearer shares	ordinary shares	none	12,000,000	12,000	11,999,700.00 as in-kind contribution, 300.00 in cash	28.02.2007	31.12.2006
B	bearer shares	ordinary shares	none	2,183,500	2,183	by shares in Centrum Teleradiologii Enel-Med Sp. z o.o.	31.07.2008	01.01.2008
C	bearer shares	ordinary shares	none	2,283,400	2,283 in cash		31.05.2010	01.01.2009
D	bearer shares	ordinary shares	none	7,100,000	7,100	in cash - shares offering on stock exchange	14.06.2011	14.06.2011
Total number of shares				23,566,900	23,567			
Total initial capital					23,567			
Nominal value per one share in PLN					1.00			

Shareholders	Number of shares (pcs)	Number of votes	Nominal value (in PLN)	Percent in the initial capital
Koremia Investments Ltd	7,124,000	7,124,000	7,124,000	30.23%
Versinus Ltd	7,123,950	7,123,950	7,123,950	30.23%

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.**(All amounts are stated in PLN thousand unless otherwise indicated)**

Smerona Holdings Ltd	992,800	992,800	992,800	4.21%
Elvestra Ltd	972,650	972,650	972,650	4.13%
Generali Otwarty Fundusz Emerytalny	2,377,000	2,377,000	2,377,000	10.09%
OFE PZU "Złota Jesień" i DFE PZU	1,400,000	1,400,000	1,400,000.00	5.94%
Akcjonariusze pozostali	3,576,500	3,576,500	3,576,500.00	15.17%
TOTAL	23,566,900	23,566,900	23,566,900.00	100.00%

NOTE 13

OWN SHARES

Not applicable.

COMPANY SHARES BEING THE PROPERTY OF SUBORDINATED UNDERTAKINGS

Not applicable.

NOTE 14

SUPPLEMENTARY CAPITAL	31.12.2013	31.12.2012
a) from sale of shares at premium	25,856	25,856
b) established under the act	4,136	4,136
c) established under the articles of association/deed, above the (minimum) value required under the act		
d) from additional payments by shareholders/partners		
e) other (by nature)		
Total supplementary capital	29,992	29,992

NOTE 15

REVALUATION RESERVE

Not applicable.

NOTE 16

OTHER RESERVE CAPITALS

Not applicable

NOTE 17

WRITE-OFFS FROM NET PROFIT DURING THE FINANCIAL YEAR

Not applicable.

NOTE 18

CHANGE IN DEFERRED INCOME TAX PROVISIONS	31.12.2013	31.12.2012
1. Deferred income tax provisions at the beginning of the period, of which:	1,488	849
a) related to financial result	1,488	849
accrued unpaid interest on loans,	142	92
fixed assets under leasing	62	81
valuation of credits and loans acc. to amortised cost		3
revenue subject to tax settlement in the next year	32	36
difference in balance-sheet value and tax value of fixed assets	1,252	637

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

b) related to equity		
c) related to goodwill or negative goodwill		
2. Increases	708	665
a) related to financial result for the period with respect to positive temporary differences (as a result of)	708	665
accrued unpaid interest on loans	32	51
difference in balance-sheet value and tax value of fixed assets	583	614
valuation of credits and loans acc. to amortised cost	13	
fixed assets under leasing	80	
b) related to equity with respect to positive temporary differences (as a result of)		
c) related to goodwill or negative goodwill with respect to positive temporary differences (as a result of)		
3. Decreases	32	26
a) related to financial result for the period with respect to positive temporary differences (as a result of)		26
fixed assets under leasing		19
revenue subject to tax settlement in the next year	32	4
valuation of credits and loans acc. to amortised cost		3
b) related to equity with respect to positive temporary differences (as a result of)		
c) related to goodwill or negative goodwill with respect to positive temporary differences (as a result of)		
4. Total deferred income tax provisions at the end of the period	2,164	1,488
a) related to financial result	2,164	1,488
accrued unpaid interest on loans	174	142
fixed assets under leasing	143	62
difference in balance-sheet value and tax value of fixed assets	1,835	1,252
valuation of credits and loans acc. to amortised cost	13	
revenue subject to tax settlement in the next year		32
b) related to equity		
c) related to goodwill or negative goodwill		

Positive temporary differences	Expiry date	31.12.2013	31.12.2012
I. ASSETS			
accrued unpaid interest on loans	31.12.2015	914	747

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

fixed assets under leasing	31.12.2017	750	326
difference in balance-sheet value and tax value of fixed assets	31.12.2020	9,658	6,591
II. LIABILITIES			
revenue subject to tax settlement in the next year	31.12.2013		166
valuation of credits and loans acc. to amortised cost	next financial year	69	
Total		11,392	7,830

CHANGE IN LONG-TERM PROVISIONS FOR PENSIONS AND SIMILAR BENEFITS (ON ACCOUNT OF)	31.12.2013	31.12.2012
a) at the beginning of the period	170	129
provisions for retirement benefits	170	129
b) increase (as a result of)	19	41
provisions for retirement benefits	19	41
c) used		
d) released		
e) at the end of the period	189	170
provisions for retirement benefits	189	170

CHANGE IN SHORT-TERM PROVISIONS FOR PENSIONS AND SIMILAR BENEFITS (ON ACCOUNT OF)	31.12.2013	31.12.2012
a) at the beginning of the period	470	375
provisions for retirement benefits	9	2
provisions for unused holidays	461	373
b) increase (as a result of)	126	95
provisions for retirement benefits		7
provisions for unused holidays	126	88
c) used (as a result of)		
d) released (as a result of)	4	
provisions for unused holidays		
provisions for retirement benefits	4	
e) at the end of the period	592	470
provisions for retirement benefits	6	9
provisions for unused holidays	586	461

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

CHANGE IN OTHER SHORT-TERM PROVISIONS (ON ACCOUNT OF)	31.12.2013	31.12.2012
a) at the beginning of the period	34	32
provision for auditing the financial statements	34	32
b) increase (as a result of)	34	34
provision for auditing the financial statements	34	34
c) used (as a result of)	34	32
provision for auditing the financial statements	34	32
d) released		
e) at the end of the period	34	34
provision for auditing the financial statements	34	34

NOTE 19

LONG-TERM LIABILITIES	31.12.2013	31.12.2012
a) due to subsidiaries		
b) due to co-subsidiaries		
c) due to affiliated undertaking		
d) due to significant investor		
e) due to partner of co-subsidiary		
f) due to parent entity		
g) due to other undertakings	26,159	32,436
- credits and loans	20,365	23,741
- relative to debt securities issued		
- other financial liabilities, of which:	3,086	4,179
under financial lease	3,086	4,179
- other (by nature)	2,707	4,516
under instalment sale agreements	2,707	4,516
Total long term-liabilities	26,159	32,436

LONG-TERM LIABILITIES WITH THE FOLLOWING REPAYMENT PERIOD AS AT THE BALANCE SHEET DATE	31.12.2013	31.12.2012
a) over 1 year to 3 years	22,006	20,952
b) between 3 years and 5 years	4,152	11,484
c) over 5 years		
Total long term-liabilities	26,159	32,436

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.**(All amounts are stated in PLN thousand unless otherwise indicated)**

LONG-TERM LIABILITIES (BY CURRENCY)	31.12.2013	31.12.2012
a) in Polish currency	26,159	32,436
b) in foreign currencies		
Total long term-liabilities	26,159	32,436

LONG-TERM LIABILITIES RELATIVE TO CREDITS AND LOANS

Name (business name) of an undertaking with legal form	Registered office	Amount of credit/loan acc. to agreement		Amount of credit/loan remaining for repayment		Interest rate conditions	Repayment date	Collaterals
		PLN	currency	PLN	currency			
Millennium Bank SA	Warsaw	10,125	PLN	6,257	PLN	WIBOR1M+ 1% margin	24.05.2017	mortgage on immovable properties, blank promissory note with promissory note agreement
ING Bank Śląski SA	Warsaw	5,043	PLN	2,714	PLN	WIBOR1M+ 1.5% margin	30.09.2017	registered pledge on plant and machinery for hospitals and clinics, assignment of rights under the insurance policy for such equipment
Siemens Finance Sp. z o.o.	Warsaw	6,862	PLN	4,039	PLN	WIBOR1M+ 2% margin	15.06.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	1,836	PLN	1,081	PLN	WIBOR1M+ 2% margin	15.06.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	551	PLN	334	PLN	WIBOR1M+ 2% margin	15.07.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	722	PLN	451	PLN	WIBOR1M+ 2% margin	15.08.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	104	PLN	66	PLN	WIBOR1M+ 2% margin	15.09.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	278	PLN	183	PLN	WIBOR1M+ 2% margin	15.10.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	304	PLN	43	PLN	WIBOR1M+ 3% margin	15.06.2015	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	12,066	PLN	4,743	PLN	WIBOR1M+ 3.3% margin	15.09.2016	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	60	PLN	5	PLN	WIBOR1M+ 3.0% margin	15.04.2015	transfer of title in the scope of medical equipment, promissory note
Siemens Finance	Warsaw	191	PLN	146	PLN	WIBOR1M+	15.04.2018	transfer of title in the scope of medical

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

Sp. z o.o.						2.0% margin		equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	235	PLN	167	PLN	WIBOR1M+ 2.0% margin	15.01.2018	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	143	PLN	117	PLN	WIBOR1M+ 2.0% margin	15.07.2018	transfer of title in the scope of medical equipment, promissory note
VB Leasing Polska S.A.	Wrocław	516	PLN	19	PLN	WIBOR1M+ 4.0% margin	28.02.2015	transfer of title in the scope of medical equipment, registered pledge agreement, promissory note
Total		39,036		20,365				

NOTE 20

SHORT-TERM LIABILITIES	31.12.2013	31.12.2012
a) due to subsidiaries		635
- trade liabilities with a maturity of:		635
- up to 12 months		635
b) due to co-subsidiaries		
c) due to affiliated undertaking		
d) due to significant investor		
e) due to partner of co-subsidiary		
f) due to parent entity		
g) due to other undertakings	33,459	39,087
- credits and loans, of which:	12,629	17,415
- long-term within the repayment period	9,038	7,350
- relative to debt securities issued		
- relative to dividends		
- other financial liabilities, of which:	1,653	1,919
under financial lease	1,653	1,919
- trade liabilities with a maturity of:	14,697	15,412
- up to 12 months	14,697	15,412
- over 12 months		
- advances received on supplies		
- commitments under bills of exchange		
- taxes, customs duties, insurance and other benefits to be paid	2,174	2,129
wages and salaries	2,305	2,210
- other (on account of)	1	2
other liabilities due to employees	1	2
h) special funds (on account of)	65	16
social fund	65	16
Total short-term liabilities	33,524	39,738

SHORT-TERM LIABILITIES (BY CURRENCY)	31.12.2013	31.12.2012
a) in Polish currency	33,471	39,689
b) in foreign currencies (acc. to currency and after conversion into PLN)	53	49

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.**(All amounts are stated in PLN thousand unless otherwise indicated)**

EUR	13	6
PLN	53	24
USD		8
PLN		25
Total short-term liabilities	33,524	39,738

SHORT-TERM LIABILITIES RELATIVE TO CREDITS AND LOANS

Name (company name) of entity	Registered office	Amount of credit/loan acc. to agreement		Amount of credit/loan remaining for repayment		Interest rate conditions	Repayment date	Collaterals
Millennium Bank SA	Warsaw	10,125	PLN	2,593	PLN	WIBOR1M+ 1% margin	30.09.2017	mortgage on immovable properties, blank promissory note with promissory note agreement
Millennium Bank SA	Warsaw	20,000	PLN	673	PLN	WIBOR1M+ 0.9% margin	granted credit limit in current account up to 24.03.2014	mortgage on immovable properties, blank promissory note with promissory note agreement
Credit Agricole Bank Polska SA	Warsaw	3,000	PLN	2,880	PLN	WIBOR1M+ 0.55% margin	granted credit limit in current account up to 9.06.2014	obligating to make all cash payments in the bank in PLN in closed form
ING Bank Śląski SA	Warsaw	5,043	PLN	1,009	PLN	WIBOR1M+ 1.5% margin	30.09.2017	registered pledge on plant and machinery for hospitals and clinics, assignment of rights under the insurance policy for such equipment
Siemens Finance Sp. z o.o.	Warsaw	304	PLN	88	PLN	WIBOR1M+ 3.0% margin	15.06.2015	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	12,066	PLN	2,674	PLN	WIBOR1M+ 3.3% margin	15.09.2016	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	60	PLN	17	PLN	WIBOR1M+ 3.0% margin	15.04.2015	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	6,862	PLN	1,593	PLN	WIBOR1M+ 2.0% margin	15.06.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	1,836	PLN	426	PLN	WIBOR1M+ 2.0% margin	15.06.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	551	PLN	127	PLN	WIBOR1M+ 2.0% margin	15.07.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	722	PLN	166	PLN	WIBOR1M+ 2.0% margin	15.08.2017	transfer of title in the scope of medical equipment, promissory note

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

Siemens Finance Sp. z o.o.	Warsaw	104	PLN	24	PLN	WIBOR1M+ 2.0% margin	15.09.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	278	PLN	63	PLN	WIBOR1M+ 2.0% margin	15.10.2017	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	191	PLN	43	PLN	WIBOR1M+ 2.0% margin	15.04.2018	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	235	PLN	53	PLN	WIBOR1M+ 2.0% margin	15.01.2018	transfer of title in the scope of medical equipment, promissory note
Siemens Finance Sp. z o.o.	Warsaw	143	PLN	26	PLN	WIBOR1M+ 2.0% margin	15.07.2018	transfer of title in the scope of medical equipment, promissory note
VB Leasing Polska S.A.	Wrocław	516	PLN	127	PLN	WIBOR1M	28.02.2015	transfer of title in the scope of medical equipment, registered pledge agreement, promissory note
VB Leasing Polska S.A.	Wrocław	390	PLN	47	PLN	WIBOR1M	30.04.2014	transfer of title in the scope of medical equipment, registered pledge agreement, promissory note
Total		62,426		12,629				

NOTE 21

OTHER ACCRUALS	31.12.2013	31.12.2012
a) accrued expenses		
b) deferred income	261	283
- long-term (on account of)	110	12
adjustment for profit from leaseback	90	
donations relative to fixed assets	20	12
- short-term (on account of)	152	271
income relative to the next year	91	266
adjustment for profit from leaseback	56	
donations relative to fixed assets	5	5
Total other accruals	261	283

NOTE 22

MANNER OF CALCULATING THE BOOK VALUE PER ONE SHARE AND DILUTED BOOK VALUE PER ONE SHARE

BOOK VALUE PER 1 SHARE	31.12.2013	31.12.2012
Book value (in PLN thousand)	44,628	44,161
Number of shares (pcs)	23,566,900	23,566,900
Book value per one share (in PLN)	1.89	1.87

NOTE 23

CONTINGENT RECEIVABLES FROM RELATED UNDERTAKINGS (ON ACCOUNT OF)	31.12.2013	31.12.2012
a) received guarantees and warranties		
b) other		
Total contingent receivables from related undertakings		

CONTINGENT LIABILITIES DUE TO RELATED UNDERTAKINGS (ON ACCOUNT OF)	31.12.2013	31.12.2012
a) granted guarantees and warranties		
b) other		
Total contingent liabilities due to related undertakings		

Notes to the profit and loss account

NOTE 24

NET REVENUE FROM SALES OF PRODUCTS (MATERIAL STRUCTURE - TYPES OF OPERATIONS)	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
Sale of medical services	199,760	180,785
of which: from related undertakings		
Total net revenue from sales of products	199,760	180,785
of which: from related undertakings		
NET REVENUE FROM SALES OF PRODUCTS (TERRITORIAL STRUCTURE)	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) domestic	199,760	180,785
of which: from related undertakings		
medical services	199,760	180,785
of which: from related undertakings		
Total net revenue from sales of products	199,760	180,785
of which: from related undertakings		

NOTE 25

REVENUE FROM SALES OF GOODS AND MATERIALS

The Company does not generate any revenue from sales of goods and materials.

NOTE 26

COSTS BY NATURE	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) amortisation and depreciation	14,107	14,460
b) consumption of materials and energy	16,849	16,450
c) outsourcing	122,531	113,014
d) taxes and other charges	182	319
e) wages and salaries	36,014	35,832
f) social insurance and other benefits	6,578	6,594
g) other costs by nature (on account of)	1,348	1,871
business trips	101	181
insurance	808	941
fees for the organisation	225	513
representation	213	236
Total costs by nature	197,608	188,540
Change in inventories, products, prepayments and accruals		

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Costs of work performed by the entity for its own purposes (negative figure)		
Costs of sales (negative figure)	-6,974	-6,805
Overheads (negative figure)	-6,048	-6,433
Manufacturing costs of products sold	184,586	175,302

NOTE 27

OTHER OPERATING INCOME	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) released provisions (for)	196	
costs - missing invoices	106	
released revaluation write-off	90	
b) other, of which:	1,177	719
prescribed liabilities written off	16	30
damages received	502	43
surplus of current assets	24	52
sale of low-value assets	13	
reimbursement of court costs, composition arrangements	7	73
sub-lease of premises	46	69
medical trainings	98	
re invoicing of costs of services	76	
coupons and vouchers	13	13
marketing activities	56	160
medical insurance - re invoicing	208	237
profit from leaseback	56	
donations	29	
other	23	41
Total other operating income	1,374	719

NOTE 28

OTHER OPERATING COSTS	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) established provisions (for)		
missing invoices - costs		
b) other, of which:	355	467

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

bad debts written-off	224	313
damages paid	87	77
costs relative to discontinued investment	3	
shortages of current assets	40	68
costs of disputable proceedings	2	5
other		4
Total other operating costs	355	467

NOTE 29

FINANCIAL INCOME RELATIVE TO INTEREST	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) on account of granted loans	167	267
from related undertakings		
from other undertakings	167	267
b) other interest	8	26
from related undertakings		
from other undertakings	8	26
Total financial income from interest	175	293

NOTE 30

FINANCIAL COSTS RELATIVE TO INTEREST	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) on account of credits and loans	1,996	2,319
to related undertakings, of which:		
to other undertakings	1,996	2,319
b) other interest	731	476
to related undertakings, of which:		
to other undertakings	731	476
Total financial costs relative to interest	2,727	2,795

OTHER FINANCIAL COSTS	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) foreign exchange losses, of which:	12	11
- realised	13	11
- unrealised	-1	

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

b) established provisions		
c) other, of which:	46	92
commissions	46	89
other		3
Total other financial costs	58	103

NOTE 31

EXTRAORDINARY PROFITS AND LOSSES

Not applicable.

NOTE 32

CURRENT INCOME TAX	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
1. Gross profit (loss)	925	-9,971
2. Differences between gross profit (loss) and income tax base (on account of)	-2,365	1,729
revenue not recognised as taxable income	-769	-523
costs not recognised as tax deductible expenses	4,141	5,312
revenue increasing taxable revenues	249	1,614
costs increasing tax costs	-5,986	-4,674
tax loss		
3. Income tax base	-1,440	-8,242
4. Income tax acc. to rate effective in each year		
5. Increases, discontinuations, exemptions, deductions and decreases of tax		
6. Current income tax recognised (stated) in tax return for the period, of which:		
- stated in the profit and loss account	51	16
- relative to items decreasing or increasing the equity		
- relative to items decreasing or increasing goodwill or negative goodwill		

The tax in the amount of PLN 16 thousand stated in the profit and loss account for the year 2012 refers to the adjustments for tax for the years 2010 and 2011, while the tax in the amount of PLN 51 thousand stated in the profit and loss account for the year 2013 refers to the adjustment for tax for the year 2009.

DEFERRED INCOME TAX STATED IN THE PROFIT AND LOSS ACCOUNT	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

- decrease (increase) with respect to recognition and reversal of temporary differences	407	-1,156
- decrease (increase) with respect to changes in tax rates		
- decrease (increase) with respect to tax loss not recognised earlier, tax relief, or temporary difference from the preceding period		
- decrease (increase) with respect to writing off the deferred income tax assets or lack of possibility to use the provisions for deferred income tax		
- other items of deferred tax (on account of)		
Total deferred income tax	407	-1,156

TOTAL AMOUNT OF DEFERRED TAX	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
- recognised in equity		
- recognised in goodwill or negative goodwill		

INCOME TAX STATED IN THE PROFIT AND LOSS ACCOUNT, RELATED TO	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
- discontinued operations		
- result of extraordinary transactions		

NOTE 33

OTHER OBLIGATORY REDUCTIONS OF PROFIT (INCREASES OF LOSS)

Not applicable.

NOTE 34

DISTRIBUTION OF NET PROFIT OR COVERING OF LOSS	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
- covering with profits from next years		-8,831
- allocation of profit to supplementary capital	467	
Total	467	-8,831

NOTE 35

MANNER OF CALCULATING PROFIT (LOSS) PER ONE ORDINARY SHARE AND DILUTED PROFIT (LOSS) PER ONE ORDINARY SHARE	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
a) net profit (loss)	467	-8,831

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

b) weighted average number of ordinary shares	23,566,900	23,566,900
- of A series	12,000,000	12,000,000
- of B series	2,183,500	2,183,500
- of C series	2,283,400	2,283,400
- of D series	7,100,000	7,100,000
c) net profit (loss) / weighted average number of ordinary shares	0.02	-0.37

Notes to the cash flow statements

NOTE 36

STRUCTURE OF CASH AND CASH EQUIVALENTS FOR CASH FLOW STATEMENT	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
- cash in hand and at bank	74	66
- other cash and cash equivalents	307	343
Total	381	409

NOTE 37

LIST OF SIGNIFICANT ADJUSTMENTS FOR CASH FLOWS FROM OPERATING ACTIVITIES RECOGNISED IN THE ITEM OF "OTHER ADJUSTMENTS"	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
1. Total adjustments - operating activities	16,983	19,883
- exceeding 5% of adjustments in operating activities	849	994
a) other adjustments of operating activities	221	260

NOTE 38

LIST OF SIGNIFICANT OTHER INFLOWS AND OUTFLOWS WITHIN INVESTMENT CASH FLOWS FROM INVESTING ACTIVITIES RECOGNISED IN THE ITEMS OF "OTHER INFLOWS FROM FINANCIAL ASSETS" AND "OTHER INVESTMENTS OUTFLOWS"	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
1. Total inflows - investing activities	359	4,011
- 5% of inflows in investing activities	18	201
a) Total other investment inflows	0	0
2. Total outflows - investing activities	2,644	18,558
5% of outflows in investing activities	132	928
a) Total other investment outflows	0	0

NOTE 39

LIST OF SIGNIFICANT OTHER INFLOWS AND OUTFLOWS WITHIN FINANCIAL CASH FLOWS FROM FINANCIAL ACTIVITIES RECOGNISED IN THE ITEMS OF "OTHER FINANCIAL INFLOWS" AND "OTHER FINANCIAL OUTFLOWS"	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
1. Total inflows - financial activities	11,598	17,357
5% of inflows in financial activities	580	868
a) Total other financial inflows	231	191
2. Total outflows - financial activities	26,793	17,979
5% of outflows in financial activities	1,340	899
a) Total other financial outflows	0	0

NOTES TO THE FINANCIAL STATEMENTS

NOTE 1. INFORMATION ON FINANCIAL INSTRUMENTS

NOTE 1.1 Categories of financial instruments

Item	Description	Financial assets held for trading
1	At the beginning of the period, of which:	
2	Increases	
3	Decreases	
4	At the end of the period, of which:	
4.1	short-term financial assets disclosed in the balance sheet	
	a) shares	
	b) debt securities	
	c) other short-term financial assets	
	d) other securities	
	e) other cash and cash equivalents	

Item	Description	Other financial liabilities
1	At the beginning of the period	47,254
2	Increases	
3	Decreases	
	- repayment	9,521
4	At the end of the period, of which:	37,733
4.1	financial liabilities disclosed in the balance sheet	37,733

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.

(All amounts are stated in PLN thousand unless otherwise indicated)

	a) other financial liabilities	4,739
	b) credits and loans	32,994

Item	Description	Granted loans and own receivables
1	At the beginning of the period, of which:	4,101
2	Increases	167
	- acquisition	167
3	Decreases	216
	- valuation	216
4	At the end of the period, of which:	4,051
4.1	long- and short-term financial assets disclosed in the balance sheet	4,051
	a) granted loans	4,051

Item	Description	Financial assets held to maturity
1	At the beginning of the period, of which:	
2	Increases	
3	Decreases	
4	At the end of the period, of which:	
4.1	long- and short-term financial assets disclosed in the balance sheet	
	a) debt securities	
	b) other securities	
	c) other short-term financial assets	

Item	Description	Financial assets available for sale
1	At the beginning of the period, of which:	
2	Increases	
3	Decreases	
4	At the end of the period, of which:	
4.1	long- and short-term financial assets disclosed in the balance sheet	
	a) shares	
	b) debt securities	
	c) other securities	
	d) other short-term financial assets	

NOTE 1.2 Description of financial instruments of the undertaking

NOTE 1.2.1 Significant information on financial instruments

A. Types of financial instruments

The Company uses the following financial instruments:

1. Other financial liabilities
 - a. Liabilities relative to credits and loans
 - b. Financial liabilities relative to financial lease
2. Granted loans

B. Methods and significant principles assumed for determining the fair value of financial assets and liabilities measured at fair value

Financial instruments are valued in the following manner:

1. As at the balance sheet date, liabilities relative to credits and loans are valued at the amount due, taking into account the adjusted acquisition price.
2. As at the balance sheet date, liabilities relative to financial lease are valued at the amount due, taking into account the adjusted acquisition price.
3. As at the balance sheet date, granted loans are valued at the amount due taking into account the adjusted acquisition price.

C. Recognition of effects of reassessment of financial assets classified to the category of available for sale

In the reporting period covering the years 2012-2013, the Company did not have any financial assets held for sale.

D. Value of financial instruments stated in the balance sheet measured at fair value and recognition of effects of their reassessment

In the reporting period covering the years 2012-2013, the Company did not reassess any financial instruments following the change in their fair value.

E. Table of changes in revaluation reserve in the scope of financial instruments

In the reporting period covering the years 2012-2013, the Company did not revalue the financial instruments which would be recognised in revaluation reserve.

F. Principles of entering financial instruments acquired in regulated market to account books

In the reporting period covering the years 2012-2013, the Company did not have any financial instruments acquired in the regulated market.

G. Exposure to interest rate risk

As at December 31, 2013, the Company had liabilities relative to credits and loans. Long-term credits granted by the banks bear the annual interest rate of WIBOR 1M+1% or WIBOR 1M+1.5%.

As at December 31, 2013, the Company had liabilities relative to using the overdraft on the current account which bears the annual interest rate of WIBOR 1M+0.9%. As at December 31, 2013, the

Company had liabilities relative to loans which bear the annual interest rate of WIBOR 3M+1.3% or WIBOR 3M+2.09% or WIBOR 3M+2.5% or WIBOR 3M+3%.

Therefore, the Company is exposed to the risk of changes in interest rates. In the future, the Company may incur higher financial costs related to debt service.

H. Exposure to credit risk

As at the balance sheet date, that is December 31, 2013, the Company had liabilities relative to long- and short term credits and loans. Therefore, the Company is exposed to the risk that a bank withdraws from the credits granted to the Company.

NOTE 1.2.2 Financial assets valued at the adjusted acquisition price

In the reporting period covering the years 2012-2013 and as at the balance sheet date, that is December 31, 2013, the Company held financial assets relative to granted loans which were valued at adjusted acquisition price taking into account the effective interest rate.

NOTE 1.2.3 Financial assets and liabilities not measured at fair value

Not applicable.

NOTE 1.2.4 Agreements concerning the conversion of financial assets into securities and/or buy-back agreements

Not applicable.

NOTE 1.2.5 Reasons for changing the principles of financial assets valuation

Not applicable.

NOTE 1.2.6 Amounts of revaluation write-offs for financial assets

Not applicable.

NOTE 1.2.7 Income from interest

	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
Income from interest on financial assets:	167	267
- held for trading		
of which: unrealised interest		
- loans granted or own receivables	167	267
of which: unrealised interest	167	267
- held to maturity		
of which: unrealised interest		
- available for sale		
of which: unrealised interest		
Total unrealised interest, of which:	167	267
- with the time-limit for payment up to 3 months		

- with the time-limit for payment between 3 and 12 months		
- with the time-limit for payment over 12 months	167	267

NOTE 1.2.8 Unrealised interest on granted loans or own receivables in the part subject to revaluation write-offs

Not applicable.

NOTE 1.2.9 Costs relative to interest on financial liabilities

	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012
Costs relative to interest on financial liabilities:	2,378	2,620
- held for trading		
of which: unrealised interest		
- other short-term financial liabilities	2,378	2,620
of which: unrealised interest		
- long-term financial liabilities		
of which: unrealised interest		
Total unrealised interest, of which:		
- with the time-limit for payment up to 3 months		
- with the time-limit for payment between 3 and 12 months		
- with the time-limit for payment over 12 months		

NOE 1.2.10 Objectives and principles of financial risk management

The Company is exposed to the following types of financial risk:

1. Interest rate risk.
2. Foreign exchange risk.
3. Credit risk.

The objective of risk management is to minimise its influence on financial results of the Company and to ensure the financial liquidity of the Company.

The Company manages the financial liabilities in a way allowing minimisation of financial costs related to debt service. Thanks to long cooperation with financial institutions, it negotiates advantageous interest rates. The Company uses other sources of financing such as subsidies. The Management Board pays significant attention to ensuring financial flows for the Company which allow timely payment of financial liabilities.

The Company is exposed to the risk of changing foreign exchange rates on account of costs of renting the space. The foreign exchange risk arises directly from the rates for rent determined in foreign currency converted into PLN. In order to minimise the influence of changing foreign exchange rates

on the financial results of the Company, the Management Board negotiates the rates for the rent of space on an on-going basis.

The Company is also exposed to the risk that the financial institutions withdraw from financing the activities of the Company. To mitigate the risk, the Company makes every effort to achieve good financial results, which results in maintaining appropriate bank ratings. The Management Board monitors - on an on-going basis - the offers of banks in the scope of credits and loans which may be used if it is necessary to acquire new source of financing.

NOTE 1.2.11 Changes in revaluation reserve in the scope of valuation of hedging instruments

Not applicable.

NOTE 2 INFORMATION ON OFF-BALANCE-SHEET ITEMS, IN PARTICULAR CONTINGENT LIABILITIES, OF WHICH ALSO GUARANTEES AND WARRANTIES GRANTED BY THE COMPANY (INCLUDING PROMISSORY NOTES)

As at December 31, 2013, the contingent liabilities of the Company equalled PLN 15,711,104 and they resulted from the promissory note collateral for promissory notes issued by Centrum Medyczne Enel-Med Sp. z o.o. to secure the liabilities arising from lease towards BFL Nieruchomości Sp. z o.o., bank guarantees granted by Millennium Bank Polska SA being the performance bonds, and court cases instituted against the Company.

NOTE 3 LIABILITIES DUE TO THE STATE BUDGET OR BUDGETS OF LOCAL SELF-GOVERNMENT UNITS UNDER ACQUIRED OWNERSHIP TITLES TO BUILDINGS AND STRUCTURES

As at the balance sheet date, that is December 31, 2013, and in the reporting period 2012-2013, the Company did not have any liabilities due to the State budget or budgets of local-self-government units under acquired ownership titles to buildings and structures.

NOTE 4 INFORMATION ON INCOMES, COSTS AND RESULTS OF OPERATIONS DISCONTINUED IN A GIVEN PERIOD OR TO BE DISCONTINUED IN THE NEXT PERIOD

Not applicable.

NOTE 5 COST OF MANUFACTURE OF FIXED ASSETS UNDER CONSTRUCTION, FIXED ASSETS MANUFACTURED FOR ITS OWN PURPOSES

Item	Description	Total outlays	of which: manufactured by own means
1	Group 1	9	
2	Group 2		
4	Group 4	215	
5	Group 5		
6	Group 6	178	
7	Group 7	998	
8	Group 8	1,233	
9	Intangible assets	170	

Total	2,803
-------	-------

NOTE 6 INVESTMENT OUTLAYS INCURRED AND PLANNED WITHIN THE NEXT 12 MONTHS OF THE BALANCE SHEET DATE, OF WHICH ON NON-FINANCIAL FIXED ASSETS

Outlays on	Incurred in the current financial year	Planned in the next financial year
1) intangible assets	170	290
2) fixed assets	2,633	12,510
- of which: related to environmental protection		
3) fixed assets under construction	580	1,700
- of which: related to environmental protection		
Total	3,383	14,500

NOTE 7 INFORMATION ON SIGNIFICANT TRANSACTIONS CONCLUDED BY THE COMPANY WITH RELATED UNDERTAKINGS PURSUANT TO NON-ARM'S LENGTH CONDITIONS, TOGETHER WITH THEIR AMOUNTS AND THE INFORMATION SPECIFYING THE NATURE OF SUCH TRANSACTIONS

Not applicable.

NOTE 8 INFORMATION ON NATURE AND ECONOMIC GOAL OF AGREEMENTS CONCLUDED BY THE COMPANY AND NOT INCLUDED IN THE BALANCE SHEET IN THE SCOPE NECESSARY TO ASSESS HOW THEY AFFECT THE MATERIAL AND FINANCIAL STANDING AND THE FINANCIAL RESULT OF THE UNDERTAKING

Not applicable.

NOTE 9 INFORMATION ON JOINT VENTURES WHICH ARE NOT SUBJECT TO CONSOLIDATION

Not applicable.

NOTE 10 INFORMATION ON AVERAGE EMPLOYMENT IN THE FINANCIAL YEAR BROKEN DOWN BY OCCUPATIONAL GROUPS

	31.12.2013	31.12.2012
Blue-collar workers	24	24
White-collar workers	569	550
Total employment	593	574

NOTE 11 TOTAL VALUE OF REMUNERATION, REWARDS OR BENEFITS (IN CASH AND IN KIND) PAID, PAYABLE OR POTENTIALLY PAYABLE, SEPARATELY FOR THE MEMBERS OF MANAGEMENT AND SUPERVISORY BODIES OF THE COMPANY

Description	01.01.2013 - 31.12.2013	01.01.2012 - 31.12.2012

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Remuneration for the Management Board, of which:	696	794
- wages and salaries	696	794
- rewards		
- benefits of which:		
- incentive or bonus programs based on the Company's equity, of which:		
- based on bonds with pre-emptive rights,		
- based on convertible bonds		
- based on subscription warrants		
- other		
Remuneration for the Supervisory Board, of which:	360	360
- wages and salaries	360	360
- rewards		
- benefits of which:		
- incentive or bonus programs based on		
- based on bonds with pre-emptive rights,		
- based on convertible bonds		
- based on subscription warrants		
- other		
Total remuneration	1,056	1,154

01.01.2013 -31.12.2013	Function	Remuneration	Rewards	Benefits
Total amount for the Management Board, of which:		696		
Adam Stanisław Rozwadowski	President of the Management Board	360		
Jacek Jakub Rozwadowski	Deputy President of the Management Board	336		
Total amount for the Supervisory Board, of which:		360		
Anna Maria Rozwadowska	Chairperson of the Supervisory Board	240		
Janusz Ryszard Jakubowski	Member of the Supervisory Board	30		
Anna Piszcz	Member of the Supervisory Board	30		

FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. for the period from 01.01 – 31.12.2013.
(All amounts are stated in PLN thousand unless otherwise indicated)

Zbigniew Okoński	Member of the Supervisory Board	30		
Adam Cihak	Member of the Supervisory Board	30		
Total remuneration		1,056		

01.01.2012 - 31.12.2012	Function	Remuneration	Rewards	Benefits
Total amount for the Management Board, of which:		794		
Adam Stanisław Rozwadowski	President of the Management Board	425		
Jacek Jakub Rozwadowski	Deputy President of the Management Board	369		
Total amount for the Supervisory Board, of which:		360		
Anna Maria Rozwadowska	Member of the Supervisory Board	228		
Janusz Ryszard Jakubowski	Member of the Supervisory Board	42		
Anna Piszcz	Member of the Supervisory Board	30		
Zbigniew Okoński	Member of the Supervisory Board	30		
Adam Cihak	Member of the Supervisory Board	30		
Total remuneration		1,154		

NOTE 12 INFORMATION ON THE VALUE OF UNPAID ADVANCES, CREDITS, LOANS, GUARANTEES, WARRANTIES, OR OTHER AGREEMENTS FOR PROVISION OF SERVICES TO THE COMPANY GRANTED BY THE COMPANY TO THE MEMBERS OF MANAGEMENT AND SUPERVISORY BODIES

As at the balance sheet date, that is December 31, 2013, the members of management and supervisory bodies do not have any financial liabilities due to the Company.

NOTE 13 INFORMATION ON AGREEMENTS WITH STATUTORY AUDITOR OR ENTITY AUTHORISED TO AUDIT, AND ON TERMS AND CONDITIONS OF REMUNERATION

Remuneration	2013	2013
--------------	------	------

Audit of annual separate financial statements	25	28
Other certifying services, of which review of separate financial statements	17	17
Tax advisory services		
Other services		
Total remuneration	42	45

NOTE 14 INFORMATION ON SIGNIFICANT EVENTS CONCERNING THE PREVIOUS YEARS AND INCLUDED IN THE FINANCIAL STATEMENTS FOR THE CURRENT PERIOD.

Did not occur.

NOTE 15 INFORMATION ON SIGNIFICANT EVENTS THAT TOOK PLACE AFTER THE BALANCE SHEET DATE, NOT INCLUDED IN THE FINANCIAL STATEMENTS

Did not occur.

NOTE 16 INFORMATION ON THE RELATIONS BETWEEN THE LEGAL PREDECESSOR AND THE COMPANY AND ON THE MANNER AND THE SCOPE OF TAKING OVER THE ASSETS AND LIABILITIES

There are no relations between legal predecessor and the Company

NOTE 17 FINANCIAL STATEMENTS ADJUSTED WITH THE INFLATION INDEX

There are no reasons to perform the adjustment for the analysed financial statements with the inflation index.

NOTE 18 DIFFERENCES BETWEEN THE DATA DISCLOSED IN THE FINANCIAL STATEMENTS AND THE COMPARABLE DATA AND THE PREVIOUSLY PREPARED AND NON-PUBLISHED FINANCIAL STATEMENTS

Did not occur.

NOTE 19 CHANGES IN THE APPLIED ACCOUNTING PRINCIPLES (POLICY) AND THE MANNER OF DRAWING UP THE FINANCIAL STATEMENTS MADE IN RELATION TO THE PREVIOUS ACCOUNTING YEAR(S), THEIR CAUSES, TITLES AND THE INFLUENCE OF RESULTING FINANCIAL EFFECTS ON MATERIAL AND FINANCIAL SITUATION, LIQUIDITY, FINANCIAL RESULT AND PROFITABILITY

Did not occur.

NOTE 20 ADJUSTMENTS FOR ERRORS MADE, THEIR CAUSES, TITLES AND THE INFLUENCE OF RESULTING FINANCIAL EFFECTS ON MATERIAL AND FINANCIAL SITUATION, LIQUIDITY, FINANCIAL RESULT AND PROFITABILITY

Did not occur.

NOTE 21 IN THE CASE OF UNCERTAINTY AS TO THE POSSIBILITY OF CONTINUING OPERATIONS AS A GOING CONCERN, A DESCRIPTION OF SUCH UNCERTAINTY AND THE STATEMENT THAT SUCH UNCERTAINTY EXISTS

The financial statements were drawn up with the assumption that the Company will continue its operations as a going concern. There are no circumstances indicating the threats to the activities in the foreseeable future.

NOTE 22 INFORMATION ON THE MERGER OF COMPANIES

Not applicable.

NOTE 23 IN THE CASE THE EQUITY METHOD IS NOT APPLIED FOR VALUATION OF SHARES IN SUBORDINATED UNDERTAKINGS IN THE FINANCIAL STATEMENTS, IT IS NECESSARY TO DESCRIBE THE EFFECTS WHICH MIGHT HAVE BEEN CAUSED BY ITS APPLICATION AND ITS EFFECT ON FINANCIAL RESULT. IN THE CASE OF UNCERTAINTY AS TO THE POSSIBILITY OF CONTINUING OPERATIONS AS A GOING CONCERN, A DESCRIPTION OF SUCH UNCERTAINTY AND THE STATEMENT THAT SUCH UNCERTAINTY EXISTS

Not applicable.

NOTE 24 REASONS OF DECISION THAT THE CONSOLIDATED FINANCIAL STATEMENTS ARE NOT DRAWN UP AND THE LEGAL GROUNDS FOR SUCH A DECISION

The Company does not draw up consolidated financial statements under the exemption arising from Article 58 of the Accounting Act.